Dana Elias
No más puestos en curso
Perfil
Dana Elias worked as a Program Director & Vice President at Andromeda Biotech Ltd.
from 2007 to 2010.
Prior to that, she held Principal positions at DeveloGen AG, Peptor Ltd, and Portman Pharmaceuticals, Inc. She received a graduate and doctorate degree from the Weizmann Institute of Science.
Antiguos cargos conocidos de Dana Elias.
| Empresas | Cargo | Fin |
|---|---|---|
| Portman Pharmaceuticals, Inc. | Corporate Officer/Principal | - |
DeveloGen AG
 DeveloGen AG Pharmaceuticals: MajorHealth Technology DeveloGen AG is a biopharmaceutical company engaged in the discovery and development of novel therapeutics for the treatment of metabolic and endocrine disorders with a particular focus on diabetes. DeveloGen develops highly innovative approaches for the treatment of diabetes and obesity targeting key pathophysiological mechanisms such as insulin resistance and loss of insulin-producing beta cells. DeveloGen's product pipeline includes two programs at advanced stages of lead optimization, a small molecule inhibitor program based on a novel and proprietary target to address insulin resistance (type 2 diabetes). A growth factor targeting beta cell regeneration (type 1 and type 2 diabetes). DeveloGen is based in Goettingen, Germany. | Corporate Officer/Principal | - |
| Peptor Ltd | Corporate Officer/Principal | - |
Andromeda Biotech Ltd.
 Andromeda Biotech Ltd. Pharmaceuticals: MajorHealth Technology Andromeda Biotech Ltd. develops treatment for autoimmune diabetes. The company was founded in 2007 and is headquartered in Rehovot, Israel. | Corporate Officer/Principal | - |
Formación de Dana Elias.
| Weizmann Institute of Science | Doctorate Degree |
Experiencias
Funciones ocupadas
Empresas relacionadas
| Empresas privadas | 4 |
|---|---|
DeveloGen AG
DeveloGen AG Pharmaceuticals: MajorHealth Technology DeveloGen AG is a biopharmaceutical company engaged in the discovery and development of novel therapeutics for the treatment of metabolic and endocrine disorders with a particular focus on diabetes. DeveloGen develops highly innovative approaches for the treatment of diabetes and obesity targeting key pathophysiological mechanisms such as insulin resistance and loss of insulin-producing beta cells. DeveloGen's product pipeline includes two programs at advanced stages of lead optimization, a small molecule inhibitor program based on a novel and proprietary target to address insulin resistance (type 2 diabetes). A growth factor targeting beta cell regeneration (type 1 and type 2 diabetes). DeveloGen is based in Goettingen, Germany. | Health Technology |
| Peptor Ltd | Health Technology |
| Portman Pharmaceuticals, Inc. | |
Andromeda Biotech Ltd.
Andromeda Biotech Ltd. Pharmaceuticals: MajorHealth Technology Andromeda Biotech Ltd. develops treatment for autoimmune diabetes. The company was founded in 2007 and is headquartered in Rehovot, Israel. | Health Technology |
- Bolsa de valores
- Insiders
- Dana Elias
